SIS Medical successfully concludes clinical study
Frauenfeld – SIS Medical has published the results of a clinical study for its lead product. This has found that the company’s high-pressure balloon catheter performs better than the balloon catheters customarily used in cardiology. SIS Medical is confident that this will play a key role in advancing its commercialization.
SIS Medical AG, a developer and manufacturer of high-quality balloon catheters from the St.GallenBodenseeArea, has successfully concluded a clinical study for its lead product, a high-pressure balloon catheter. The results have now been published in the EuroIntervention Journal. They show that it outperforms traditional scoring balloon catheters. Stents were expanded more and minimum lumen diameter increased – “a major aspect in the prevention of future cardiac complications”, as was explained in a press release.
The likelihood of restenosis was also reduced, as was the necessity to use additional instruments. The high-pressure balloon catheter cuts the cost of treatment and its duration, thereby also lowering risk for the patient.
The study was carried out in four German hospitals and in the cardiology unit of Lucerne Cantonal Hospital. Its successful end represents “a significant milestone in the history of SIS Medical AG”, said CEO Sergej Kammerzell. “This solid foundation will not only enable us to compete with notable manufacturers of scoring balloon catheters worldwide, but also to market our high-pressure balloon catheter as an effective, safe and cost-effective solution.”
Willi Zwahlen, Senior Vice President of Sales, co-founder and member of the Board of Directors, believes “this supports our strategy of approval and payback in core markets such as the USA, China and Japan”. Chairman of the Board of Directors, Hubertus Leonhardt, predicts that annual sales potential will be in the region of US$500 million.